ELAVL1 and diabetes mellitus: Ala-Gln, short for the dipeptide alanyl-glutamine, could attenuate inflammation in various experiments including intestinal mucositis, Escherichia coli lipopolysaccharide-induced vascular hyporeactivity, asthma, obesity-associated diabetes, and concomitant inflammatory via sirtuin 1/HUR signaling in β cells (Jing et al., 2007; Araújo et al., 2015; Cruzat et al., 2015; Liu et al., 2020).